AnaptysBio Analyst Price Targets

Wall Street analyst price targets and consensus rating for AnaptysBio (ANAB).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

12Buy

2Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$70Upside to Avg. PT+51.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$70→$60
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$95
Sep 23, 2026	Leerink Partners	David Risinger	PT Cut	Outperform	$90→$81
Aug 25, 2026	TD Cowen	Joseph Thome	PT Cut	Buy	$75→$70
Aug 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$95
Jun 10, 2026	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$95
May 13, 2026	UBS	Michael Yee	PT Raise	Buy	$60→$76
May 13, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$63→$75
May 4, 2026	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$95→$93
Apr 28, 2026	Leerink Partners	David Risinger	PT Raise	Outperform	$66→$85
Apr 22, 2026	Barclays	Etzer Darout	PT Cut	Overweight	$79→$63
Apr 21, 2026	UBS	Michael Yee	PT Cut	Buy	$90→$60
Mar 31, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$67→$95
Mar 30, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$66
Mar 17, 2026	UBS	Michael Yee	PT Raise	Buy	$70→$90
Mar 12, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$60→$75
Mar 9, 2026	Truist Securities	John Lee	PT Raise	Hold	$36→$50
Mar 5, 2026	Stifel	Alex Thompson	PT Raise	Buy	$56→$85
Mar 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$78→$79
Mar 4, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$51→$66

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

HC Wainwright & Co. analyst Joseph Pantginis assumes AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $95.

Benzinga Newsdesk

AnaptysBio Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

AnaptysBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

People Also Watch

People Also Watch

AnaptysBio Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

AnaptysBio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PROHC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PROLeerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PROTD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PROHC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PROHC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81

PRO
TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

PRO
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target

PRO
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95